Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF SAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION  SVRA

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (THE COMPANY) (NASDAQ: SVRA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED ADDITIONAL ANALYSES FROM ITS PIVOTAL PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM IN APAP WERE PRESENTED AS POSTER PRESENTATIONS AT THE ERS CONGRESS 2025 IN AMSTERDAM, THE NETHERLANDS. ERS 2025 POSTERS SAVARA TITLE: EFFICACY OF INHALED MOLGRAMOSTIM ACCORDING TO SEVERITY OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP).

SAVARA PRESENTS NEW DATA FROM THE PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2025

LOS ANGELES , SEPT. 25, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SVRA

LOS ANGELES--(BUSINESS WIRE)--SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SVRA.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK, SEPT. 18, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF SAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS  SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT AN INVESTOR FILED A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF SAVARA INC. (NASDAQ: SVRA), BETWEEN MARCH 7, 2024 AND MAY 23, 2025, BOTH DATES INCLUSIVE (THE CLASS PERIOD). SAVARA IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW FIRM IS INVESTIGATING THE ALLEGA.

ROSEN LAW FIRM URGES SAVARA INC. (NASDAQ: SVRA) STOCKHOLDERS WITH LARGE LOSSES TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK--(BUSINESS WIRE)---- $SVRA #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. (SAVARA OR THE COMPANY) (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. THE FIRM HAS RE.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (THE COMPANY) (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED AN INCREASED ESTIMATE OF AUTOIMMUNE PAP DIAGNOSED PREVALENCE IN THE U.S. THE UPDATED ANALYSIS INDICATES AN ~50% LARGER AUTOIMMUNE PAP PATIENT POPULATION IN THE U.S. THAN THE COMPANY'S PREVIOUSLY ESTIMATED CLAIMS ANALYSIS FROM 2023 (~5,500 AUTOIMMUNE PAP PATIENTS VERSUS ~3,600). THE RECENT ANALYSIS OF HEALTH CLAIMS DATA WAS.

SAVARA ANNOUNCES NEW U.S. HEALTH CLAIMS DATA ANALYSIS FINDS OVER 50% INCREASE IN THE ESTIMATED NUMBER OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) PATIENTS COMPARED TO PREVIOUS CLAIMS ANALYSIS

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED MEMBERS OF THE MANAGEMENT TEAM WILL HOST 1X1 MEETINGS AND PRESENT AT TWO UPCOMING HEALTHCARE CONFERENCES. WELLS FARGO SECURITIES HEALTHCARE CONFERENCE SEPTEMBER 3, 2025, 4:30PM ET/1:30PM PT H.C. WAINWRIGHT GLOBAL HEALTHCARE CONFERENCE SEPTEMBER 9, 2025, 1:00PM ET/10:00AM PT THE LIVE WEBCASTS AND SUBSEQUENT REPLAYS WILL BE A.

SAVARA ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR HEALTHCARE CONFERENCES

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, ANNOUNCED THAT THE RESULTS FROM THE PHASE 3 IMPALA-2 CLINICAL TRIAL WILL BE PUBLISHED ONLINE IN NEJM. THE MANUSCRIPT, TITLED A PHASE 3 TRIAL OF INHALED MOLGRAMOSTIM THERAPY IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS WILL APPEAR IN THE AUGUST 21, 2025, ONLINE VERSION OF THE PUBLICATION AND CAN BE FOUND AT WWW.NEJM.ORG. FOLLOWING THE ONLIN.

NEW ENGLAND JOURNAL OF MEDICINE (NEJM) TO PUBLISH RESULTS FROM SAVARA'S PIVOTAL PHASE 3 IMPALA-2 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE ACCEPTANCE OF THREE ABSTRACTS FOR POSTER PRESENTATION AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2025, SEPTEMBER 27  OCTOBER 1, AMSTERDAM, THE NETHERLANDS. THE COMPANY WILL ALSO HOST AN INDUSTRY EVENING MINI SYMPOSIUM TITLED ADVANCES IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS AT THE MEETING. ERS CONGRESS 2025.

SAVARA TO PRESENT NEW DATA FROM THE PHASE 3 IMPALA-2 TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE EUROPEAN RESPIRATORY SOCIETY CONGRESS 2025

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDING JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE. FOLLOWING A RECENT TYPE A MEETING WITH THE FDA, AND RECEIPT OF THE MEETING MINUTES, WE BELIEVE WE HAVE ALIGNED ON A PATH FORWARD FOR THE INFORMATION NEEDED TO RESUBMIT THE BLA WITH FUJIFILM AS OUR DRUG SUBSTANCE MANUFACTURER, SAID MATT PA.

Savara Inc.

SVRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Savara Inc.

SVRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SVRA